<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02844036</url>
  </required_header>
  <id_info>
    <org_study_id>38RC13.440</org_study_id>
    <nct_id>NCT02844036</nct_id>
  </id_info>
  <brief_title>Angioplasty of Distal Lesions for Carriers of Inoperable Post-embolic HTP</brief_title>
  <acronym>OCT²EPH</acronym>
  <official_title>Angioplasty of Distal Lesions for Carriers of Inoperable Post-embolic HTP</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Grenoble</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Grenoble</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Currently, the standard treatment for proximal thromboses lesions responsible for
      post-embolic pulmonary hypertension, is the surgical thromboendarterectomy. When the ravages
      are judged too distal or the patient is judged inoperable for a curative surgical gesture,
      there is no evidence of any therapeutic option, exept for K anti-vitamins for recurrent
      embolism. Prognosis is then pejorative with a 60% mortality at 5 years.

      This study propose an alternative treatment for these patients in therapeutic &quot;dead end&quot;.
      This is about applying arterial thrombosis technique to the pulmonary circulation.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Actual">October 2017</completion_date>
  <primary_completion_date type="Actual">October 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percutaneous angioplasty</measure>
    <time_frame>About 90 minutes</time_frame>
    <description>International Normalized Ratio wil be measure and need to be between 2 and 3.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Balloon angioplasty</measure>
    <time_frame>About 90 minutes</time_frame>
    <description>Same mode than valscular or coronal angioplasty.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Right heart catheterization</measure>
    <time_frame>Few minutes</time_frame>
    <description>Right auricular pressure auriculaire droite moyenne ou POD (mmHg)
Blood pressure : systolic, diastolic, and average(mmHg)
pression artérielle pulmonaire d'occlusion (PAPO) moyenne (mmHg)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Echocardiography</measure>
    <time_frame>Few minutes</time_frame>
    <description>Right ventricular heart function with evaluation of :
- The maximum pressure gradient (mmHg)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Walking test</measure>
    <time_frame>6 minutes</time_frame>
    <description>Start heart rate (T0) and at the end (T6) of the test (bpm)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Functional respiratory investigations</measure>
    <time_frame>About an hour</time_frame>
    <description>Forced expiratory volume (FEV) ml/kg
Forced vital capacity (FVC) ml/kg
Total lung capacity ml/kg
Alveolar capillarytransfer of Carbon monoxide (CO) ml/kg
Transfer coefficient of CO (KCO) ml/kg
All volumes in ml/kg</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pulmonary tomography or pulmonary angiography</measure>
    <time_frame>About 30 minutes</time_frame>
    <description>tomography (CT) or angiography</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Heart rate</measure>
    <time_frame>Few minutes</time_frame>
    <description>Heart rate (bpm) during right heart catheterization.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cardiac output (L/min)</measure>
    <time_frame>Few minutes</time_frame>
    <description>Cardiac output (L/min) during right heart catheterization.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Venous oxygen saturation (%)</measure>
    <time_frame>Few minutes</time_frame>
    <description>Venous oxygen saturation (%) during right heart catheterization.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Echocardiography</measure>
    <time_frame>Few minutes</time_frame>
    <description>Right ventricular heart function with evaluation of :
Surface area of the right ventricle (cm²)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Echocardiography</measure>
    <time_frame>Few minutes</time_frame>
    <description>Right ventricular heart function with evaluation of :
Cardiac output (L/min) and cardiac index (L/min/m²)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Walking test</measure>
    <time_frame>6 minutes</time_frame>
    <description>Patient self evaluation of the dyspnea on a Borg scale from 0 (not breathless) to 10 (serious breathless)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Walking test</measure>
    <time_frame>6 minutes</time_frame>
    <description>Arterial blood saturation in oxygen measured by an oxymeter dat the beginning (T0) and at the end of the test (T6) (SO2)</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">33</enrollment>
  <condition>Pulmonary Hypertension</condition>
  <arm_group>
    <arm_group_label>Patients with a pulmonary hypertension</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pulmonary hypertension group 4 of Dana point, chronic thromboses lesions, thromboembolic.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Percutaneous angioplasty</intervention_name>
    <arm_group_label>Patients with a pulmonary hypertension</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Balloon angioplasty</intervention_name>
    <arm_group_label>Patients with a pulmonary hypertension</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Right heart catheterization</intervention_name>
    <arm_group_label>Patients with a pulmonary hypertension</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Echocardiography</intervention_name>
    <arm_group_label>Patients with a pulmonary hypertension</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>A six-minute walking test</intervention_name>
    <arm_group_label>Patients with a pulmonary hypertension</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Functional respiratory investigations</intervention_name>
    <arm_group_label>Patients with a pulmonary hypertension</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Pulmonary tomography or pulmonary angiography</intervention_name>
    <arm_group_label>Patients with a pulmonary hypertension</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Biological parameters</intervention_name>
    <arm_group_label>Patients with a pulmonary hypertension</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients over 18 years

          -  Patients with a pulmonary hypertension diagnosed by right catheterisation, with a mean
             arterial pressure &gt;30 mmHg and arterial pulmonary resistance &gt; 3 UW.

          -  Patients with group 4 (Dana point) pulmonary hypertension, thromboembolic.

          -  Chronic thrombosis visible to scanner, pulmonary IRM angiogram or to pulmonary
             angiogram.

          -  Patient's file refused by the reference center multidisciplinary coordination meetings
             for surgical thromboendartériectomy or refusal from the patient to be operate.

          -  Absence of counter-argument to the femoral venous or jugular way.

          -  Normal kidney function or moderatly degraded (clearance&gt;30 mL) or dialysed renal
             failure

          -  Persons affiliated to national social security

          -  Signed free consent by patients

        Exclusion Criteria:

          -  Pulmonary hypertension pos-embolic operated by thromboendarteriectomy

          -  Pulmonary hypertension Group 1 of Dana Point, meaning idiopathic, familial,
             post-anorectics, associate with a congenital heart disease associated to a
             scleroderma, associated to a chronic hemolytic disease

          -  Pulmonary hypertension Group 2 of Dana Point, associated with a left cardiovascular
             disease

          -  Pulmonary hypertension Group 3 of Dana Point, associated to a respiratory disease

          -  Pulmonary hypertension Group 5 of Dana Point, of unclear or multifactorial mechanism

          -  Hypersensitivity to HEXABRIX, to iodinated contrast product or one of its components

          -  Obvious thyrotoxicosis

          -  Protected major persons

          -  Pregnant or breastfeeding women

          -  Persons deprived of liberty

          -  Persons in emergency situations.

          -  No consent signed or approoved

          -  Persons no affiliated to national social security
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hélène Bouvaist, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Grenoble Hospital University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UniversityHospitalGrenoble</name>
      <address>
        <city>La Tronche</city>
        <zip>38700</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Mizoguchi H, Ogawa A, Munemasa M, Mikouchi H, Ito H, Matsubara H. Refined balloon pulmonary angioplasty for inoperable patients with chronic thromboembolic pulmonary hypertension. Circ Cardiovasc Interv. 2012 Dec;5(6):748-55. doi: 10.1161/CIRCINTERVENTIONS.112.971077. Epub 2012 Nov 27.</citation>
    <PMID>23192917</PMID>
  </reference>
  <reference>
    <citation>Sugimura K, Fukumoto Y, Satoh K, Nochioka K, Miura Y, Aoki T, Tatebe S, Miyamichi-Yamamoto S, Shimokawa H. Percutaneous transluminal pulmonary angioplasty markedly improves pulmonary hemodynamics and long-term prognosis in patients with chronic thromboembolic pulmonary hypertension. Circ J. 2012;76(2):485-8. Epub 2011 Dec 15.</citation>
    <PMID>22185711</PMID>
  </reference>
  <reference>
    <citation>Fukumoto Y, Shimokawa H. Recent progress in the management of pulmonary hypertension. Circ J. 2011;75(8):1801-10. Epub 2011 Jul 11. Review.</citation>
    <PMID>21747194</PMID>
  </reference>
  <reference>
    <citation>Feinstein JA, Goldhaber SZ, Lock JE, Ferndandes SM, Landzberg MJ. Balloon pulmonary angioplasty for treatment of chronic thromboembolic pulmonary hypertension. Circulation. 2001 Jan 2;103(1):10-3.</citation>
    <PMID>11136677</PMID>
  </reference>
  <reference>
    <citation>Jaïs X, D'Armini AM, Jansa P, Torbicki A, Delcroix M, Ghofrani HA, Hoeper MM, Lang IM, Mayer E, Pepke-Zaba J, Perchenet L, Morganti A, Simonneau G, Rubin LJ; Bosentan Effects in iNopErable Forms of chronIc Thromboembolic pulmonary hypertension Study Group. Bosentan for treatment of inoperable chronic thromboembolic pulmonary hypertension: BENEFiT (Bosentan Effects in iNopErable Forms of chronIc Thromboembolic pulmonary hypertension), a randomized, placebo-controlled trial. J Am Coll Cardiol. 2008 Dec 16;52(25):2127-34. doi: 10.1016/j.jacc.2008.08.059.</citation>
    <PMID>19095129</PMID>
  </reference>
  <reference>
    <citation>Diggle PJ, Liang KY, Zeger SL. Analysis of longitudinal data. New York: Oxfiord University Press, 2000.</citation>
  </reference>
  <reference>
    <citation>Twisk JWR. Applied longitudinal analysis for epidemiology. Cambridge: Cambridge University Press, 2003.</citation>
  </reference>
  <reference>
    <citation>Mayer E, Jenkins D, Lindner J, D'Armini A, Kloek J, Meyns B, Ilkjaer LB, Klepetko W, Delcroix M, Lang I, Pepke-Zaba J, Simonneau G, Dartevelle P. Surgical management and outcome of patients with chronic thromboembolic pulmonary hypertension: results from an international prospective registry. J Thorac Cardiovasc Surg. 2011 Mar;141(3):702-10. doi: 10.1016/j.jtcvs.2010.11.024.</citation>
    <PMID>21335128</PMID>
  </reference>
  <reference>
    <citation>Pepke-Zaba J, Jansa P, Kim NH, Naeije R, Simonneau G. Chronic thromboembolic pulmonary hypertension: role of medical therapy. Eur Respir J. 2013 Apr;41(4):985-90. doi: 10.1183/09031936.00201612. Epub 2013 Feb 8. Review.</citation>
    <PMID>23397304</PMID>
  </reference>
  <reference>
    <citation>de Perrot M, McRae K, Shargall Y, Pletsch L, Tan K, Slinger P, Ma M, Paul N, Moric J, Thenganatt J, Mak S, Granton JT. Pulmonary endarterectomy for chronic thromboembolic pulmonary hypertension: the Toronto experience. Can J Cardiol. 2011 Nov-Dec;27(6):692-7. doi: 10.1016/j.cjca.2011.09.009. Epub 2011 Oct 21.</citation>
    <PMID>22018451</PMID>
  </reference>
  <reference>
    <citation>Inami T, Kataoka M, Shimura N, Ishiguro H, Yanagisawa R, Taguchi H, Fukuda K, Yoshino H, Satoh T. Pulmonary edema predictive scoring index (PEPSI), a new index to predict risk of reperfusion pulmonary edema and improvement of hemodynamics in percutaneous transluminal pulmonary angioplasty. JACC Cardiovasc Interv. 2013 Jul;6(7):725-36. doi: 10.1016/j.jcin.2013.03.009. Epub 2013 Jun 14.</citation>
    <PMID>23769649</PMID>
  </reference>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 15, 2016</study_first_submitted>
  <study_first_submitted_qc>July 25, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 26, 2016</study_first_posted>
  <last_update_submitted>October 20, 2017</last_update_submitted>
  <last_update_submitted_qc>October 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Distal Lesions</keyword>
  <keyword>Post-embolic HTP</keyword>
  <keyword>Angioplasty</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension, Pulmonary</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

